What is the Work Group's recommendation for treatment with RASi in patients with diabetes and CKD with severely increased albuminuria?
The Work Group issued a strong (1B) recommendation for treatment with ACEi or ARB for patients with diabetes, increased albuminuria, and normal-to-low GFR (G1 G4; A2 or A3), because their desirable benefits in kidney and CV protection outweigh the adverse risks associated with therapy.